Bevacizumab biosimilar is under clinical development by Bio-Thera Solutions and currently in Phase I for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData, Phase I drugs for Recurrent Glioblastoma Multiforme (GBM) have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Bevacizumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Bevacizumab biosimilar overview

Bevacizumab biosimilar  (Pobevcy) is a recombinant humanized monoclonal IgG1 antibody, acts as an anti-neoplastic agent. It is formulated as injectable solution concentrate, for intravenous route of administration. Pobevcy is indicated for the treatment of advanced, metastatic or recurrent non-small cell lung cancer and metastatic colorectal cancer.

Bevacizumab biosimilar is under development for the treatment of hepatocellular carcinoma, metastatic breast cancer, metastatic colorectal cancer, non-small cell lung cancer, ovarian cancer, renal cell carcinoma, fallopian tube cancer, primary peritoneal cancer, epithelial ovarian cancer, metastatic rectal cancer, recurrent glioblastoma and cervical cancer. It is administered through intravenous route. The drug candidate targets vascular endothelial growth factor A.

It was also under development for glioblastoma multiforme.

Bio-Thera Solutions overview

Bio-Thera Solutions (Bio-Thera) is a clinical-stage biopharmaceutical company that carries out the research and development and production of innovative drugs and biosimilars. The company’s pipeline products include humanized monoclonal antibodies and peptide drugs such as BAT8001, BAT8003, BAT1306, BAT2094, and BAT4306F. It also offers BAT1406, an adalimumab biosimilar; BAT1706, a bevacizumab biosimilar; BAT1806, a tocilizumab biosimilar; and BAT2506. The company develops its products and therapies for the treatment of indications such as cancer, autoimmune diseases, cardiovascular diseases, arthritis, Crohn’s disease, psoriasis, polyarticular juvenile idiopathic arthritis (PJIA), and systemic juvenile idiopathic arthritis (SJIA). Bio-Thera is headquartered in Guangzhou, Guangdong, China.

For a complete picture of Bevacizumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.